- Home
- HSPO vs XLO Comparison
HSPO vs XLO Comparison
Compare HSPO & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- XLO
- Stock Information
- Founded
- HSPO 2014
- XLO 2016
- Country
- HSPO United States
- XLO United States
- Employees
- HSPO N/A
- XLO N/A
- Industry
- HSPO Blank Checks
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- HSPO Finance
- XLO Health Care
- Exchange
- HSPO Nasdaq
- XLO Nasdaq
- Market Cap
- HSPO 49.4M
- XLO 42.2M
- IPO Year
- HSPO 2022
- XLO 2021
- Fundamental
- Price
- HSPO $12.11
- XLO $1.07
- Analyst Decision
- HSPO
- XLO Buy
- Analyst Count
- HSPO 0
- XLO 1
- Target Price
- HSPO N/A
- XLO $4.00
- AVG Volume (30 Days)
- HSPO 3.5K
- XLO 2.9M
- Earning Date
- HSPO 01-01-0001
- XLO 05-08-2025
- Dividend Yield
- HSPO N/A
- XLO N/A
- EPS Growth
- HSPO N/A
- XLO N/A
- EPS
- HSPO N/A
- XLO N/A
- Revenue
- HSPO N/A
- XLO $9,274,000.00
- Revenue This Year
- HSPO N/A
- XLO $299.61
- Revenue Next Year
- HSPO N/A
- XLO $1.99
- P/E Ratio
- HSPO $34.81
- XLO N/A
- Revenue Growth
- HSPO N/A
- XLO N/A
- 52 Week Low
- HSPO $10.97
- XLO $0.62
- 52 Week High
- HSPO $12.41
- XLO $1.70
- Technical
- Relative Strength Index (RSI)
- HSPO 66.53
- XLO 64.52
- Support Level
- HSPO $11.82
- XLO $0.86
- Resistance Level
- HSPO $12.14
- XLO $0.92
- Average True Range (ATR)
- HSPO 0.02
- XLO 0.11
- MACD
- HSPO 0.03
- XLO 0.02
- Stochastic Oscillator
- HSPO 91.43
- XLO 77.18
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).